Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked disease caused by a deficiency of the enzyme iduronate-2-sulphatase (IDS), which results in the lysosomal accumulation of glycosaminoglycans (GAG). This paper describes a knockout mouse model of MPS II which has been used to assess the effect of enzyme replacement therapy. Therapy with IDS results in a marked decrease in urinary GAGs, as well as reduced GAG accumulation in several tissues. These studies have been used to support the first clinical trial of recombinant IDS in patients with Hunter syndrome.
Muenzer
J
J
Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina 27599-7487, USA. Joseph_muenzer@med.unc.edu
Lamsa
J C
JC
Garcia
A
A
Dacosta
J
J
Garcia
J
J
Treco
D A
DA
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D006801:Humans; D007066:Iduronate Sulfatase / Q000627:therapeutic use*; D051379:Mice; D018345:Mice, Knockout; D016532:Mucopolysaccharidosis II / Q000188:drug therapy*
D007066:Iduronate Sulfatase